XML 39 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Components

Note 3—Balance Sheet Components

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

March 31,
2023

 

 

December 31,
2022

 

Prepaid research and development

 

$

4,710

 

 

$

4,840

 

Prepaid clinical trial

 

 

2,568

 

 

 

2,119

 

Deferred offering costs

 

 

724

 

 

 

724

 

Prepaid insurance

 

 

373

 

 

 

388

 

Prepaid bonus

 

 

26

 

 

 

18

 

Other

 

 

532

 

 

 

448

 

Total prepaid expenses and other current assets

 

$

8,933

 

 

$

8,537

 

 

Property, plant and equipment, net consisted of the following (in thousands):

 

 

 

March 31,
2023

 

 

December 31,
2022

 

Leasehold improvements

 

$

2,091

 

 

$

2,091

 

Laboratory equipment

 

 

2,868

 

 

 

2,868

 

Computer equipment

 

 

1,115

 

 

 

1,115

 

Furniture and fixtures

 

 

908

 

 

 

898

 

Construction in progress

 

 

9,633

 

 

 

9,633

 

 

 

16,615

 

 

 

16,605

 

Accumulated depreciation

 

 

(1,973

)

 

 

(1,642

)

Property, plant and equipment, net

 

$

14,642

 

 

$

14,963

 

 

In November 2022, the Company recognized a non-cash impairment charge of $36.4 million for the manufacturing facility asset group, of which $26.3 million relates to construction in progress and finance lease right-of-use assets. The impairment charge was estimated using a discounted cash flow model and recorded in the consolidated statements of operations for the year ended December 31, 2022. Property, plant and equipment, net includes $1.2 million and $1.3 million of assets capitalized as finance leases as of March 31, 2023 and December 31, 2022, respectively.

Depreciation expense was $0.3 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively.

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

 

March 31,
2023

 

 

December 31,
2022

 

Accrued research and development

 

$

6,451

 

 

$

8,190

 

Accrued severance

 

 

3,027

 

 

 

1,463

 

Accrued clinical trial

 

 

2,462

 

 

 

1,473

 

Lease liabilities, current portion

 

 

1,752

 

 

 

1,521

 

Accrued compensation

 

 

1,242

 

 

 

2,519

 

Accrued professional and consulting fees

 

 

866

 

 

 

390

 

Accrued property, plant and equipment

 

 

112

 

 

 

2,081

 

Other

 

 

690

 

 

 

650

 

Total accrued expenses and other current liabilities

 

$

16,602

 

 

$

18,287